Fate laughs at probability
Edward George Earle Lytton Bulwer-Lytton, 1st Baron Lytton PC Outcomes of people with acute myeloid leukemia (AML) are diverse even in those receiving similar therapies: some die early never achieving cytologic complete remission, others achieve cytologic complete remission but relapse whilst still others never have leukemia recurrence and appear cured. Many subject-, disease-related and therapyrelated variables are reported to predict prognosis of cohorts of persons with AML. However, accuracy and precision in predicting outcomes in a person at diagnosis is imperfect: concordance (C-) statistics derived from the receiveroperator characteristic curves are only 0.7-0.8 (for binary outcomes, no predictive value is 0.5 and perfect predictive value is 1.0) [1, 2] . This inaccuracy (getting the wrong answer) and imprecision (getting different answers with repeated use) persists for subsequent outcomes even in persons achieving cytology-defined complete remission (typically defined by ≤5 percent myeloblasts in the bone marrow). Results of tests of measurable residual disease (MRD) using multi-parameter flow cytometry (MPFC), quantitative PCR (qPCR), and next-generation sequencing (NGS) platforms are claimed to improve leukemia relapse estimates [3] . But to what degree do they? Current assays are imperfect in identifying leukemia cells which, if left untreated, cause relapse, and as currently used their contribution to refining outcomes prediction is suboptimal [4] . In this issue of LEUKEMIA, Zeijlemaker and colleagues [5] describe MPFC quantitation of abnormal CD34-positive CD38-negative (CD34 + CD38 − ) cells as a technique to improve accuracy and prediction of leukemia relapse in persons with AML remission after induction and consolidation therapy. Their previously described method [6] to detect these immune phenotype abnormal cells is relying on aberrant expression of ≥1 cell surface molecule on cells to differentiate abnormal from normal CD34 + CD38 − hematopoietic cells. Although the relationship between phenotype and cell stem function remains controversial, measuring the concentration of cells with abnormal immune phenotypes improved outcome prediction compared with conventional approaches. This assay was used in 594 persons with AML 18−66 years at diagnosis and 302 people achieving a cytologic complete remission after induction chemotherapy in a recent HOVON/SAKK trial [5] . Zeijlemaker and colleagues report their CD34 + CD38 − assay used at diagnosis can stratify subjects into cohorts with different probabilities of achieving a cytologic complete remission and surviving. However, only the survival prediction was statistically significant in multi-variable analyses casting doubt on its predictive value as there are many competing causes of death unrelated to the probability of death from leukemia such as fatal infections or CNS bleeds in persons who would otherwise have achieved a cytologic complete remission. Data from testing after completing induction chemotherapy suggested detection of abnormal CD34
+ CD38
− cells is independently associated with an increased cumulative incidence of relapse and briefer survival [5] . Importantly, data reported by Zeijlemaker and colleagues suggest CD34 + CD38 − testing can increase accuracy of currently used MPFC and qPCR-based MRD assays in predicting outcomes in that subjects with two positive assays had worse outcomes than subjects with one positive test. Persons with no positive test had the best outcomes. This finding resembles recent reports that NGS-based MRDtesting increases predictive accuracy when combined with MPFC [7, 8] .
Work toward improving MRD assays and harmonizing and standardizing them for use across institutions and laboratories is ongoing [9] . The study by Zeijlemaker [10] . Finally, development of a new test to predict an increased cumulative risk of relapse and worse relapse-free survival is encouraging. The challenge is to integrate data from MRDtesting and related platforms to facilitate high-confidence predictions of the fate of someone with AML. These efforts may also result in a better understanding of leukemia biology and thereby improve therapy outcomes.
